Clinical trial
Inhaled Steroid Reduces Systemic Inflammation in COPD
NCT00175565 · University of British Columbia, Other · Completed
Key facts
| NCT number | NCT00175565 |
|---|---|
| Title | Inhaled Steroid Reduces Systemic Inflammation in COPD |
| Official title | Effects of Fluticasone On Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease |
| Lead sponsor | University of British Columbia, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis |
| Intervention type | Drug |
| Interventions | inhaled fluticasone 500 mcg b.i.d. |
| Enrollment | 50 |
| Start date | Jan 1, 2002 |
| Completion | Jul 1, 2003 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 28, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: